YDES

AI MemoPost-earnings T+3

Breeze Acquisition

As of 2026-07-23/Post-earnings T+3/Confidence low

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-23 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

low

Horizon

—

Key catalyst

Post-earnings verification remains unresolved • 2026-07-23

Base target: $2 / p=55% prob

Biggest risk

FY2025 net loss was approximately $8.3 million, operating expenses rose to about $5.4 million, and the company reported lower gross margin from a less favorable product mix. The July 20 earnings trigger is not corroborated by a confirmed company release, and analyst revisions or target changes are unavailable. Clinical timing, transaction completion, and commercialization remain execution-dependent.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

YD Bio has reported 17% FY2025 revenue growth, approximately $6.0 million of cash, expanded U.S. diagnostic access, and multiple planned regulatory milestones. Successful execution on diagnostics utilization, IND filings, or the EG BioMed transaction could support a higher valuation. [#PR-EARNINGS-2026-05-01] [#PR-2026-07-02]

Research note

Recommendation

—

Confidence

low

As of

2026-07-23

Base target

p=55%

Bull target

p=15%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Diagnostics footprint follow-through
2026 LSC/exosome IND and OkaiDx regulatory milestones
YD Bio has reported 17% FY2025 revenue growth, approximately $6.0 million of cash, expanded U.S.

BearKey bullets

Coverage is low, analyst targets are unavailable, and the peer set is based mainly on same-sector market capitalization rather than direct operating comparability.
FY2025 net loss and operating expenses were substantial relative to approximately $6.0 million of reported cash; cash runway and financing needs are not sufficiently established.
Gross margin declined as the sales mix shifted toward lower-margin pharmaceuticals and medical peripherals.

WatchKey bullets

Post-earnings verification remains unresolved

Summary

High-level snapshot

Recommendation

Model confidence

low

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $2 (p=55%)

Target spread vs base: +59% / -43%

Scenario probabilities

Bull Target: $4 (p=15%)Base Target: $2 (p=55%)Bear Target: $1 (p=30%)

Commentary

Company-originated news is directionally constructive but thin, centered on the July 2 laboratory-footprint update and the older FY2025 release. The packet provides a $2.21 anchor price on 2026-07-22 but no controlled post-earnings event-window return. Social, options, short-interest, and employee-sentiment data are unavailable; the neutral values above indicate missing coverage, not positive evidence. No reliable analyst revision or target-change signal was found.

As of 2026-07-23 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Diagnostics footprint follow-through
2026 LSC/exosome IND and OkaiDx regulatory milestones

Scenarios

Bull Target (Scenario probability)

$4 / p=15% prob

Base Target (Scenario probability)

$2 / p=55% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Analysis 2026-07-23 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.15

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-23
Post-earnings verification remains unresolved
The queue identifies 2026-07-20 as an earnings date, but the verified company materials available are the FY2025 results and a July 2 operating update. No confirmed July 20 release, consensus surprise, guidance change, analyst revision, or attributed post-print reaction was found. This is a monitoring item rather than a confirmed positive catalyst. [#PR-EARNINGS-2026-05-01]
Prob 10.00% • Move 0.00% • Priced-in 0.00%
EVENT2026-10-21
EG BioMed transaction decision
The proposed EG BioMed merger remains a non-binding transaction expected by the company to close in 2026, subject to definitive agreements, approvals, and other conditions. Completion could broaden the diagnostics platform, while delay or failure would remove a key strategic narrative. [#PR-2026-07-02]
Prob 20.00% • Move 30.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Diagnostics footprint follow-through
2026-10-21
YD Bio reported that affiliated laboratory licensing expanded its authorized U.S. footprint to 46 states plus Washington, D.C. and Guam, supporting early cancer-detection testing and real-world molecular-data generation. The announcement is already public; incremental value depends on demonstrated utilization and monetization. [#PR-2026-07-02]
Prob 35% • Move 15% • Priced-in 35%

Long-term Catalysts

Months to a year

2026 LSC/exosome IND and OkaiDx regulatory milestones
2027-07-23
Management reported completed CMC work and FDA DMF filings for its limbal stem-cell and exosome platforms, with planned 2026 IND submissions for dry-eye disease and age-related macular degeneration. It also described a planned FDA Q-Submission for OkaiDx pancreatic-cancer detection. Timing and regulatory outcomes remain uncertain. [#PR-EARNINGS-2026-05-01]
Prob 25% • Move 35% • Priced-in 20%

Risks

Coverage is low, analyst targets are unavailable, and the peer set is based mainly on same-sector market capitalization rather than direct operating comparability.
FY2025 net loss and operating expenses were substantial relative to approximately $6.0 million of reported cash; cash runway and financing needs are not sufficiently established.
Gross margin declined as the sales mix shifted toward lower-margin pharmaceuticals and medical peripherals.
IND, Q-Submission, clinical-validation, and commercialization timing depends on preclinical work, manufacturing readiness, regulatory feedback, and execution.
No confirmed July 20 earnings release, earnings surprise, guidance update, analyst revision, or post-print market-reaction attribution was located.
The EG BioMed merger is non-binding and may not close on the anticipated timeline or terms.

Peers

Symbol	Summary
ABOS	Same-sector market-cap proxy at roughly $160 million; direct clinical or program comparability is not established.
ADCT	Same-sector market-cap proxy at roughly $158 million; useful for size context but not a confirmed direct peer.
MOLN	Same-sector market-cap proxy at roughly $154 million; direct indication and pipeline overlap are unverified.
PYXS	Same-sector market-cap proxy at roughly $160 million; included for size context rather than close business comparability.
RCEL	Same-sector market-cap proxy at roughly $152 million; direct therapeutic and commercial comparability is unverified.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-23

Loading AI feed…

Symbol

Summary

ABOS

Same-sector market-cap proxy at roughly $160 million; direct clinical or program comparability is not established.

ADCT

Same-sector market-cap proxy at roughly $158 million; useful for size context but not a confirmed direct peer.

MOLN

Same-sector market-cap proxy at roughly $154 million; direct indication and pipeline overlap are unverified.

PYXS

Same-sector market-cap proxy at roughly $160 million; included for size context rather than close business comparability.

RCEL

Same-sector market-cap proxy at roughly $152 million; direct therapeutic and commercial comparability is unverified.